Technology
Health
Biotechnology
Anavex
$3.089876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$3.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.02 (-0.65%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Anavex and other stocks, options, ETFs, and crypto commission-free!
About
Anavex Life Sciences Corp. Common Stock, also called Anavex, is a clinical stage biopharmaceutical company, which engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Read More Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Employees
13
Headquarters
New York, New York
Founded
2004
Market Cap
144.41M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
386.76K
High Today
$3.19
Low Today
$3.01
Open Price
$3.15
Volume
170.50K
52 Week High
$4.35
52 Week Low
$1.25
Collections
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Therapy
Pharmaceutical
2015 IPO
News
MoneyShowMar 19
Anavex: Searching for Treatments to Parkinson's and Alzheimer's
03/19/2019 5:00 am EST Focus: HEALTHCARE Anavex (AVXL) is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, notes small cap expert Tom Bishop, editor of BI Research. Its lead candidate, Anavex2-73 (A2-73) is currently conducting a Phase 2b/3 clinical trial on Alzheimer’s. A2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors (rather than amyloid plaques), with a clean safety profile that shows pr...
StreetInsiderMar 18
Anavex Life Sciences (AVXL) Reports First Patient Dosed in Phase 2 Clinical Trial of ANAVEX2-73 for Treatment of Rett Syndrome in U.S.
Anavex Life Sciences Corp. (NASDAQ: AVXL) today announced that it has dosed the first patient in its U.S. Phase 2 double-blind, randomized, placebo-controlled, safety and efficacy trial of ANAVEX®2-73 for the treatment of Rett syndrome, a rare and catastrophic neurodevelopmental disease. ANAVEX®2-73 has already received orphan drug designation from the FDA for the treatment of Rett syndrome. “We are very pleased to report the first patient dosing of the ANAVEX®2-73 Rett syndrome Phase 2 study in the U.S.,...
Yahoo FinanceMar 13
Anavex Life Sciences to Present at the 31st Annual ROTH Conference 2019
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present at the 31st Annual ROTH Confere...
Price Paid on Robinhood
7% Lower
Right Now
52 Week Low
$1.25
Average Price Paid
$3.33
52 Week High
$4.35
Earnings
-$0.16
-$0.13
-$0.09
-$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected May 9, Pre-Market